Pros | Among most bought funds within the category. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 6/8 | ||
Category | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 2 Years 3 Months | 13 Years 2 Months | ||
Fund AUM | ₹2011 Cr | ₹8459 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.93% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.34%) Divi's Laboratories Ltd (8.34%) Lupin Ltd (6.4%) Glenmark Pharmaceuticals Ltd (6.09%) Max Healthcare Institute Ltd Ordinary Shares (6.07%) | Sun Pharmaceuticals Industries Ltd (13.55%) Lupin Ltd (7.59%) Divi's Laboratories Ltd (6.9%) Cipla Ltd (6.33%) Dr Reddy's Laboratories Ltd (5.83%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (96.98%) Basic Materials (3.02%) | Health (100%) | ||
Equity % | 98.38% | 99.45% | ||
Debt % | - | - | ||
P/E | 43.69 | 35.82 | ||
P/B | 6.61 | 5.53 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.04% | -0.6% | ||
3-Month Return | 0.24% | -0.49% | ||
6-Month Return | 6.79% | 1.7% | ||
1-Year Return | 6.41% | 0.48% | ||
3-Year Return | - | 22.57% | ||
5-Year Return | - | 16.5% |
Sharpe | - | 0.98 | ||
Alpha | - | -0.21 | ||
Beta | - | 0.91 | ||
Standard Deviation | - | 15.24 | ||
Information Ratio | - | -0.48 |
Description | HDFC Pharma and Healthcare Fund is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhruv Muchhal,Nikhil Mathur | Sailesh Raj Bhan,Divya Sharma,Kinjal Desai,Lokesh Maru |